DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Darexaban
Darexaban
From Vitamin K Antagonism to New Oral Anticoagulants: Basic Concepts
New Oral Anticoagulants Combined with Antiplatelet Therapy in the Treatment of Coronary Heart Disease: an Updated Meta-Analysis
Risk of Drug-Induced Liver Injury with the New Oral Anticoagulants
Low Molecular Weight Heparin Versus Other Anti-Thrombotic Agents For
Horizons in Novel Oral Anticoagulation Therapy In
New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary
Efficacy and Toxicity of Factor Xa Inhibitors
CHAPTER 1 General Introduction
Spontaneous Spinal Epidural Hematoma Associated with Apixaban Therapy: a Report of Two Cases
New Anticoagulants for Thromboprophylaxis After Total Knee Arthroplasty
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update Executive Summary
Noacs): the Tide Continues to Come In
Clinical Evidence of the Role of Edoxaban in Anticoagulation
Anticoagulant Agents for Acute Coronary Syndromes
W O 2014/151535 a L 2 5 September 2014 (25.09.2014) P O P C T
Xabans As Direct Factor Xa Inhibitors
Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism
The 50-Year Quest to Replace Warfarin Jeffrey Weitz
Top View
( 12 ) United States Patent
Direct Oral Anticoagulants
Molecular Recognition at the Active Site of Factor Xa
C19) United States C12) Patent Application Publication C10) Pub
TEG LY30 of Hyperfibrinolytic Trauma Patients Compared to Healthy Controls Citrated Rapid TEG LY30
Darexaban ISN 150-CL-201 Acute Coronary Syndrome CONFIDENTIAL Eudract Number 2008-005972-29
Results and the Model Development Are Described in Detail in a Separate Pharmacokinetic/Pharmacodynamic Report
Original Article Efficacy and Safety of Oral Direct Factor Xa Inhibitor for Thromboprophylaxis After Total Hip Or Knee Replacement: a Meta-Analysis
Bleeding Risk Under Oral Factor Xa Inhibitors: Meta-Analysis of the Randomized Comparison with Vitamin K Antagonists and Meta-Regression Analysis
Factors Affecting the Formation and Treatment of Thrombosis by Natural
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
New Antithrombotic Drugs in Acute Coronary Syndrome
Designing Direct and Indirect Factor Xa Inhibitors
SUPPLEMENTARY MATERIAL Supplementary Appendix
C19) United States C12) Patent Application Publication C10) Pub
New Oral Anticoagulants in Addition to Single Or Dual Antiplatelet Therapy After an Acute Coronary Syndrome: a Systematic Review and Meta-Analysis
Acute Coronary Syndromes
Is There a Role for Novel Oral Anticoagulants in Patients with an Acute Coronary Syndrome? a Review of the Clinical Trials